Buda Juice Q1 Earnings Beat Expectations with $3.5M Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 13 2026
0mins
Source: seekingalpha
- Earnings Highlights: Buda Juice reported a Q1 non-GAAP EPS of $0.05 with revenues of $3.5 million, reflecting a 16.7% year-over-year increase and exceeding market expectations by $0.3 million, indicating strong performance and growth potential in the market.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $0.8 million, demonstrating effective cost control alongside revenue growth, which enhances investor confidence in its future development prospects.
- Free Cash Flow: Buda Juice generated free cash flow of $1.1 million, indicating robust cash generation from operations that can support its expansion strategy and future investment plans, further solidifying its market position.
- Expansion Strategy: The positive financial results provide strong support for Buda Juice's expansion strategy, which is expected to drive greater market share and brand influence in the competitive beverage industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BUDA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BUDA
About BUDA
Buda Juice, Inc. operates in a beverage industry, focused on UltraFresh juice-offering cold-crafted citrus-based drinks. The Company offers an end-to-end cold chain platform that always delivers cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. Its product portfolio consists of fresh citrus juice, a fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using its cold chain process. Its products include Buda Juice (Organic), Buda Fresh - Value-Forward Offering (Non-Organic), and Private Label Products (Non-organic and Organic). Buda Fresh includes Fresh 12 oz Lime Juice, 16 oz and 128 oz Lemon Juice, Fresh Orange and Grapefruit Juice (16 oz, 32 oz and 52 oz), and Fresh Citrus-based Lemonades and Limeades (16 oz and 52 oz). Private Label Products include Fresh Citrus Line (52 oz) and Fresh Citrus-based Lemonades and Limeades (52 oz).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Buda Juice Q1 Earnings Beat Expectations with $3.5M Revenue
- Earnings Highlights: Buda Juice reported a Q1 non-GAAP EPS of $0.05 with revenues of $3.5 million, reflecting a 16.7% year-over-year increase and exceeding market expectations by $0.3 million, indicating strong performance and growth potential in the market.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $0.8 million, demonstrating effective cost control alongside revenue growth, which enhances investor confidence in its future development prospects.
- Free Cash Flow: Buda Juice generated free cash flow of $1.1 million, indicating robust cash generation from operations that can support its expansion strategy and future investment plans, further solidifying its market position.
- Expansion Strategy: The positive financial results provide strong support for Buda Juice's expansion strategy, which is expected to drive greater market share and brand influence in the competitive beverage industry.
See More
Buda Juice to Host Q1 2026 Earnings Call
- Earnings Call Announcement: Buda Juice will host a conference call on May 13, 2026, at 11:00 a.m. Eastern Time to discuss its financial and operational results for Q1 2026, indicating the company's commitment to transparency and investor communication.
- Live Webcast Details: The call will be available via a live webcast on the company's Investor Relations page, providing convenient access for investors to stay updated on the latest developments, thereby enhancing investor engagement.
- Cold Chain Infrastructure Advantage: Buda Juice's proprietary cold chain platform ensures an 8 to 12-day shelf life for its products, preserving freshness and nutrient quality, which highlights the company's competitive edge and innovation in the fresh juice market.
- Market Positioning and Strategy: As the pioneer of the Ultra Fresh™ category, Buda Juice enables retailers to offer ready-to-drink products without additional infrastructure, meeting consumer demand for fresh, healthy beverages and further solidifying its leadership position in the market.
See More
Buda Juice Reports Strong FY Results with $12.61M Revenue
- Financial Highlights: Buda Juice, Inc. reported a FY GAAP EPS of $0.20 and revenue of $12.61 million, reflecting an 11.9% year-over-year growth, indicating strong performance and growth potential in the cold chain market.
- Adjusted EBITDA: The company reported an adjusted EBITDA of $3.8 million, showcasing improved operational efficiency, which enhances investor confidence in its profitability.
- Free Cash Flow: Buda Juice generated free cash flow of $3.0 million, demonstrating robust capital management that provides ample funding for future expansion and investments.
- IPO Expectations: Buda Juice priced its initial public offering at $20 million, with positive market response, which is expected to further boost the company's market share and brand influence in the cold chain industry.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
- Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
- SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
- Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
- Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
- Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
- SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.
See More
Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors
- Successful Financing: Aktis Oncology priced its upsized IPO at $318 million, achieving a market cap of $1 billion, marking the first significant deal of 2026 and demonstrating strong market interest in its radiopharmaceuticals targeting solid tumors.
- Technological Edge: The company's alpha-emitting radiopharmaceuticals have shown superior efficacy in preclinical studies compared to Padcev, although it faces risks due to its early-stage pipeline, yet its unique treatment approach may attract investor attention.
- Market Performance: Aktis saw a 24% increase in its stock price during its first week of trading, reflecting investor recognition of its potential market value and providing a solid foundation for future financing and R&D efforts.
- Industry Outlook: With the rising demand for targeted therapies, Aktis's successful IPO not only enhances its visibility in the biotech sector but may also stimulate financing activities for similar companies, fostering growth across the industry.
See More
Buda Juice Q1 Earnings Beat Expectations with $3.5M Revenue
- Earnings Highlights: Buda Juice reported a Q1 non-GAAP EPS of $0.05 with revenues of $3.5 million, reflecting a 16.7% year-over-year increase and exceeding market expectations by $0.3 million, indicating strong performance and growth potential in the market.
- Adjusted EBITDA: The company achieved an adjusted EBITDA of $0.8 million, demonstrating effective cost control alongside revenue growth, which enhances investor confidence in its future development prospects.
- Free Cash Flow: Buda Juice generated free cash flow of $1.1 million, indicating robust cash generation from operations that can support its expansion strategy and future investment plans, further solidifying its market position.
- Expansion Strategy: The positive financial results provide strong support for Buda Juice's expansion strategy, which is expected to drive greater market share and brand influence in the competitive beverage industry.
See More
Buda Juice to Host Q1 2026 Earnings Call
- Earnings Call Announcement: Buda Juice will host a conference call on May 13, 2026, at 11:00 a.m. Eastern Time to discuss its financial and operational results for Q1 2026, indicating the company's commitment to transparency and investor communication.
- Live Webcast Details: The call will be available via a live webcast on the company's Investor Relations page, providing convenient access for investors to stay updated on the latest developments, thereby enhancing investor engagement.
- Cold Chain Infrastructure Advantage: Buda Juice's proprietary cold chain platform ensures an 8 to 12-day shelf life for its products, preserving freshness and nutrient quality, which highlights the company's competitive edge and innovation in the fresh juice market.
- Market Positioning and Strategy: As the pioneer of the Ultra Fresh™ category, Buda Juice enables retailers to offer ready-to-drink products without additional infrastructure, meeting consumer demand for fresh, healthy beverages and further solidifying its leadership position in the market.
See More
Buda Juice Reports Strong FY Results with $12.61M Revenue
- Financial Highlights: Buda Juice, Inc. reported a FY GAAP EPS of $0.20 and revenue of $12.61 million, reflecting an 11.9% year-over-year growth, indicating strong performance and growth potential in the cold chain market.
- Adjusted EBITDA: The company reported an adjusted EBITDA of $3.8 million, showcasing improved operational efficiency, which enhances investor confidence in its profitability.
- Free Cash Flow: Buda Juice generated free cash flow of $3.0 million, demonstrating robust capital management that provides ample funding for future expansion and investments.
- IPO Expectations: Buda Juice priced its initial public offering at $20 million, with positive market response, which is expected to further boost the company's market share and brand influence in the cold chain industry.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, although a backlog of startups indicated IPO plans, the overall deal count and proceeds fell below the ten-year average, reflecting cautious market sentiment.
- Sector Dynamics: The industrial sector's EquipmentShare.com led with $747 million raised, surging 33% on its first day, indicating strong investor demand for fast-growing companies viewed as resistant to AI disruption.
- SPAC Issuance Surge: January saw SPAC issuance reach a four-year high with 25 blank check deals raising $5.2 billion, providing hundreds of pre-IPO companies with an alternative path to public markets, reflecting growing interest in emerging technology firms.
- Active IPO Pipeline: By the end of January, the IPO pipeline included 216 companies seeking to raise approximately $12.4 billion, with 130 having filed or updated within the last 90 days, demonstrating ongoing market interest in new public offerings.
See More
2026 IPO Market Starts Steadily with $2.6 Billion Raised
- IPO Market Performance: In January 2026, nine IPOs raised a total of $2.6 billion, reflecting a cautious market sentiment as this figure fell short of the ten-year average, particularly after the volatility experienced in Q4 2025.
- Sector Dynamics: The industrial sector led the month’s largest IPOs, with EquipmentShare.com raising $747 million, highlighting investor preference for fast-growing companies perceived as resilient to AI disruption.
- Emerging Trends: The fintech and biotech sectors showed signs of recovery at the start of 2026, notably with fintech PicPay becoming the first Brazilian IPO in four years, raising $434 million, although its shares fell 5% post-IPO.
- SPAC Activity: January saw SPAC issuance reach a four-year high with 25 deals raising $5.2 billion, indicating growing interest in pre-IPO companies opting for SPAC mergers, despite overall IPO activity remaining below 2021 peaks.
See More
Aktis Oncology Prices Upsized IPO at $318 Million, Targets Solid Tumors
- Successful Financing: Aktis Oncology priced its upsized IPO at $318 million, achieving a market cap of $1 billion, marking the first significant deal of 2026 and demonstrating strong market interest in its radiopharmaceuticals targeting solid tumors.
- Technological Edge: The company's alpha-emitting radiopharmaceuticals have shown superior efficacy in preclinical studies compared to Padcev, although it faces risks due to its early-stage pipeline, yet its unique treatment approach may attract investor attention.
- Market Performance: Aktis saw a 24% increase in its stock price during its first week of trading, reflecting investor recognition of its potential market value and providing a solid foundation for future financing and R&D efforts.
- Industry Outlook: With the rising demand for targeted therapies, Aktis's successful IPO not only enhances its visibility in the biotech sector but may also stimulate financing activities for similar companies, fostering growth across the industry.
See More
